GlassScriptPhysician profile
Robert Priday Mildenhall
NPI 1750692042
$10,304.81
in general payments reported to CMS, 2019-2025
31 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $495 · 2021: $525 · 2022: $760 · 2023: $224 · 2024: $6,778 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,516 · Food and Beverage: $1,060 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,516.24 |
| Food and Beverage | $1,060.15 |
| Travel and Lodging | $877.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,663.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $594.54 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.58 | 2019-2022 | |
| Medtronic, INC. | $358.82 | 2021-2024 | Arcpoint, Illumisite |
| Astrazeneca Pharmaceuticals LP | $329.26 | 2019-2025 | |
| Insmed, INC. | $325.99 | 2020-2023 | Arikayce |
| Grifols USA, LLC | $232.94 | 2019-2022 | |
| Pulmonx Corporation | $226.37 | 2019-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Galvanize Therapeutics, INC | $213.56 | 2025 | Aliya System |
| Philips North America LLC | $139.65 | 2019-2020 | |
| Mylan Specialty L.P. | $108.08 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $97.30 | 2020-2022 | |
| Electromed, INC. | $95.35 | 2019-2022 | |
| Baxter Healthcare | $59.04 | 2022 | |
| Mallinckrodt Enterprises LLC | $56.77 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $56.25 | 2020-2022 | |
| Pfizer INC. | $44.23 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $39.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $38.54 | 2019-2020 | |
| Genzyme Corporation | $34.86 | 2021 | |
| Amgen INC. | $29.65 | 2022 | |
| Csl Behring | $23.49 | 2019 | |
| Covidien LP | $21.59 | 2020 | |
| Circassia INC. | $19.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.81 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.18 | 2019 | |
| Genentech USA, INC. | $15.02 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.89 | 2021 | |
| Boston Scientific Corporation | $14.32 | 2023 | Exalt Model D |
| Merck Sharp & Dohme LLC | $11.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mildenhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.